CN104800838A - MUC1-Fc多肽疫苗及其制备方法和应用 - Google Patents
MUC1-Fc多肽疫苗及其制备方法和应用 Download PDFInfo
- Publication number
- CN104800838A CN104800838A CN201510175146.4A CN201510175146A CN104800838A CN 104800838 A CN104800838 A CN 104800838A CN 201510175146 A CN201510175146 A CN 201510175146A CN 104800838 A CN104800838 A CN 104800838A
- Authority
- CN
- China
- Prior art keywords
- muc1
- immunoglobulin
- section
- carrier
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 97
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 87
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 85
- 229960005486 vaccine Drugs 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000000427 antigen Substances 0.000 claims abstract description 62
- 102000036639 antigens Human genes 0.000 claims abstract description 62
- 108091007433 antigens Proteins 0.000 claims abstract description 62
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims abstract description 61
- 102100034256 Mucin-1 Human genes 0.000 claims abstract description 61
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 48
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 48
- 241000588724 Escherichia coli Species 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 230000006801 homologous recombination Effects 0.000 claims description 8
- 238000002744 homologous recombination Methods 0.000 claims description 8
- 230000036571 hydration Effects 0.000 claims description 8
- 238000006703 hydration reaction Methods 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 229920001610 polycaprolactone Polymers 0.000 claims description 6
- 239000004632 polycaprolactone Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 238000013461 design Methods 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 241001597008 Nomeidae Species 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 201000001514 prostate carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 239000000969 carrier Substances 0.000 abstract description 2
- 230000002147 killing effect Effects 0.000 abstract description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 4
- 230000003213 activating effect Effects 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000002086 nanomaterial Substances 0.000 description 6
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- -1 TFA-α Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510175146.4A CN104800838B (zh) | 2015-04-14 | 2015-04-14 | MUC1‑Fc多肽疫苗及其制备方法和应用 |
PCT/CN2015/092338 WO2016165301A1 (zh) | 2015-04-14 | 2015-10-20 | MUC1-Fc多肽疫苗及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510175146.4A CN104800838B (zh) | 2015-04-14 | 2015-04-14 | MUC1‑Fc多肽疫苗及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104800838A true CN104800838A (zh) | 2015-07-29 |
CN104800838B CN104800838B (zh) | 2018-01-09 |
Family
ID=53686316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510175146.4A Active CN104800838B (zh) | 2015-04-14 | 2015-04-14 | MUC1‑Fc多肽疫苗及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104800838B (zh) |
WO (1) | WO2016165301A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016165301A1 (zh) * | 2015-04-14 | 2016-10-20 | 苏静 | MUC1-Fc多肽疫苗及其制备方法和应用 |
WO2017219974A1 (zh) * | 2016-06-22 | 2017-12-28 | 本康生物制药(深圳)有限公司 | 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用 |
CN108743939A (zh) * | 2018-08-07 | 2018-11-06 | 中国医学科学院生物医学工程研究所 | 共载抗原、mpla与imq的阳离子磷脂-聚合物杂化纳米粒疫苗佐剂及制备方法与应用 |
CN114028539A (zh) * | 2021-09-13 | 2022-02-11 | 北京大学 | 粘蛋白1在抑制冠状病毒中的应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11000603B2 (en) | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1481899A (zh) * | 2002-09-13 | 2004-03-17 | 新的肿瘤抗原疫苗及其制备方法和疫苗组合物 | |
WO2007087420A2 (en) * | 2006-01-23 | 2007-08-02 | Recopharma Ab | Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof |
CN103372205A (zh) * | 2012-04-26 | 2013-10-30 | 上海复和泰生物技术有限公司 | 糖基化muc1抗原致敏的肿瘤树突状细胞疫苗制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003228067B2 (en) * | 2002-04-22 | 2008-05-29 | Recopharma Ab | Mucin fusion polypeptide vaccines, compositions and methods of use thereof |
CN104800838B (zh) * | 2015-04-14 | 2018-01-09 | 深圳市中联生物科技开发有限公司 | MUC1‑Fc多肽疫苗及其制备方法和应用 |
-
2015
- 2015-04-14 CN CN201510175146.4A patent/CN104800838B/zh active Active
- 2015-10-20 WO PCT/CN2015/092338 patent/WO2016165301A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1481899A (zh) * | 2002-09-13 | 2004-03-17 | 新的肿瘤抗原疫苗及其制备方法和疫苗组合物 | |
WO2007087420A2 (en) * | 2006-01-23 | 2007-08-02 | Recopharma Ab | Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof |
CN103372205A (zh) * | 2012-04-26 | 2013-10-30 | 上海复和泰生物技术有限公司 | 糖基化muc1抗原致敏的肿瘤树突状细胞疫苗制备方法 |
Non-Patent Citations (2)
Title |
---|
EIRIKUR SAELAND ET AL: "The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma", 《CANCER IMMUNOL IMMUNOTHER》 * |
李鹏等: "纳米颗粒疫苗研究进展", 《河南农业科学》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016165301A1 (zh) * | 2015-04-14 | 2016-10-20 | 苏静 | MUC1-Fc多肽疫苗及其制备方法和应用 |
WO2017219974A1 (zh) * | 2016-06-22 | 2017-12-28 | 本康生物制药(深圳)有限公司 | 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用 |
CN109689692A (zh) * | 2016-06-22 | 2019-04-26 | 本康生物制药(深圳)有限公司 | 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用 |
CN109689692B (zh) * | 2016-06-22 | 2021-11-12 | 本康生物制药(深圳)有限公司 | 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用 |
CN108743939A (zh) * | 2018-08-07 | 2018-11-06 | 中国医学科学院生物医学工程研究所 | 共载抗原、mpla与imq的阳离子磷脂-聚合物杂化纳米粒疫苗佐剂及制备方法与应用 |
CN108743939B (zh) * | 2018-08-07 | 2021-08-20 | 中国医学科学院生物医学工程研究所 | 共载抗原、mpla与imq的阳离子磷脂-聚合物杂化纳米粒疫苗佐剂及制备方法与应用 |
CN114028539A (zh) * | 2021-09-13 | 2022-02-11 | 北京大学 | 粘蛋白1在抑制冠状病毒中的应用 |
CN114028539B (zh) * | 2021-09-13 | 2024-04-26 | 北京大学 | 粘蛋白1在抑制冠状病毒中的应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2016165301A1 (zh) | 2016-10-20 |
CN104800838B (zh) | 2018-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jiang et al. | Turning the old adjuvant from gel to nanoparticles to amplify CD8+ T cell responses | |
Saeed et al. | Engineering nanoparticles to reprogram the tumor immune microenvironment for improved cancer immunotherapy | |
CN104800838A (zh) | MUC1-Fc多肽疫苗及其制备方法和应用 | |
Zhang et al. | Peptide-based materials for cancer immunotherapy | |
Fang et al. | Engineering autologous tumor cell vaccine to locally mobilize antitumor immunity in tumor surgical bed | |
Wang et al. | Enzyme‐catalyzed formation of supramolecular hydrogels as promising vaccine adjuvants | |
Han et al. | Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development | |
Rudra et al. | A self-assembling peptide acting as an immune adjuvant | |
Li et al. | Rational design of polymeric hybrid micelles to overcome lymphatic and intracellular delivery barriers in cancer immunotherapy | |
Chen et al. | STING activator c-di-GMP-loaded mesoporous silica nanoparticles enhance immunotherapy against breast cancer | |
Saleh et al. | Multifunctional nanoparticles for cancer immunotherapy | |
Chang et al. | Extracellular vesicles with possible roles in gut intestinal tract homeostasis and IBD | |
CN104926944B (zh) | 多靶点复合抗原负载cd8+细胞毒性t淋巴细胞的制备方法及其用途 | |
Zhang et al. | Poly (ethylene glycol)-mediated assembly of vaccine particles to improve stability and immunogenicity | |
Liu et al. | BSA‐AIE nanoparticles with boosted ROS generation for immunogenic cell death immunotherapy of multiple myeloma | |
Lv et al. | Redox-responsive hyperbranched poly (amido amine) and polymer dots as a vaccine delivery system for cancer immunotherapy | |
JP2021508313A (ja) | 腫瘍関連抗原エピトープの微生物叢(microbiota)配列変異体 | |
Dai et al. | Immune-regulating bimetallic metal-organic framework nanoparticles designed for cancer immunotherapy | |
Zhong et al. | A novel liposomal vaccine improves humoral immunity and prevents tumor pulmonary metastasis in mice | |
CN113368053B (zh) | 一种装载溶瘤肽的聚合物囊泡及其与囊泡免疫佐剂、pd-1单抗的联合用药 | |
Huang et al. | Quaternized cationic carbon dots as antigen delivery systems for improving humoral and cellular immune responses | |
CN101643497A (zh) | Lmp2a蛋白来源的hla-a2限制性表位多肽及其用途 | |
Robles-Planells et al. | Chitosan-based nanoparticles for intracellular delivery of ISAV fusion protein cDNA into melanoma cells: a path to develop oncolytic anticancer therapies | |
JP6292632B2 (ja) | ポリカチオン性トリブロックコポリマーとポリアニオン性ポリマーと生理活性ペプチドを含む組成物 | |
CN110269931B (zh) | 一种水凝胶肿瘤疫苗的制备方法以及由其制备的水凝胶肿瘤疫苗和其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160316 Address after: Nanshan District city of Shenzhen province Guangdong Taoyuan street 518055 Liuxian Avenue No. 1183 Nanshan Valley Innovation Industrial Park Comprehensive Service Building 506-508 Applicant after: Shenzhen Zhonglian Biological Technology Development Co., Ltd. Address before: 518055, Shenzhen, Guangdong, Nanshan District, Taoyuan street, Tian Lao Industrial Zone, A building, two West Applicant before: Su Jing |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200122 Address after: 518000, Shenzhen, Guangdong, Nanshan District province Taoyuan street, Tian Lao industrial A District 9, west of the two floor Patentee after: BENHEALTH BIOPHARMACEUTIC (SHENZHEN) Co.,Ltd. Address before: Nanshan District city of Shenzhen province Guangdong Taoyuan street 518055 Liuxian Avenue No. 1183 Nanshan Valley Innovation Industrial Park Comprehensive Service Building 506-508 Patentee before: SHENZHEN ZHONGLIAN BIOTECHNOLOGY Co.,Ltd. |